Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Dermatologic Therapy · 2022-12 · 35 (12)
DOI: 10.1111/dth.15871 ↗At a glance
Beobachtungsstudie in Dermatologic Therapy, published online on 2022-12-01. Written by Husein Husein-ElAhmed and 4 co-authors. Institution: Department of Dermatology and Venereology, Hospital de Baza, Granada, Spain. Major MEDLINE topics: Alopecia Areata. Cited 12 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Tofacitinib is a pan‐janus kinase inhibitor (JAK) which has been tested off‐label in alopecia areata (AA) with promising results. However, evidence of tofacitinib in real‐life setting is still poor. We evaluated long‐term efficacy and safety of tofacitinib for refractory AA. This is a prospective, open‐label, observational, single‐center cohort study conducted between January 2018 and December 2020. Primary end‐point was the percent change in Severity of Alopecia Tool (SALT) at the basal visit and at the most recent follow‐up visit. Three categories of treatment response were analyzed. Data on 47 participants of Arab‐Asian heritage were analyzed. A complete and partial regrowth was observed in 18 patients (41.86%) and 11 patients (25.58%), respectively. In 12 patients (27.9%), no response was obtained. Most of the non‐responders belonged to the alopecia universalis group (66.67%). No statistical differences were observed in rates of regrowth between pediatric and adult individuals ( p = 0.52), nor between women and men. Significant differences in the average duration of tofacitinib treatment were obtained among the three categories of regrowth ( p < 0.003), notably duration of AA did not impact the clinical regrowth ( p = 0.62). To the best of our knowledge, this is the first prospective, observational, long‐term study using tofacitinib in refractory AA. Rates of regrowth and side effects are analogous to previous works. Length of tofacinitib therapy should last for 12 months before considering any discontinuation or change, since early cessation can lead to treatment failures or incomplete regrowth. Maintenance therapy after complete regrowth has demonstrated to be safe and effective to prevent recurrences of hair loss.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology and Venereology, Hospital de Baza, Granada, Spain.
- Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
- Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.
- Weill Cornell Medicine-Qatar, College of Medicine, Doha, Qatar.
- Qatar University, Medical School, Doha, Qatar.
- Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.
ORCID profiles: Husein Husein-ElAhmed
Cite
APA
Husein-ElAhmed, H., Abdulla, N., Al-Obaidli, A., Ali-Alam, M., & Steinhoff, M. (2022). Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population. Dermatologic Therapy, 35(12). https://doi.org/10.1111/dth.15871
Vancouver
Husein-ElAhmed H, Abdulla N, Al-Obaidli A, Ali-Alam M, Steinhoff M. Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population. Dermatologic Therapy. 2022;35(12). doi:10.1111/dth.15871
BibTeX
@article{HuseinElAhmed2022,
author = {Husein-ElAhmed, Husein and Abdulla, Nada and Al-Obaidli, Amina and Ali-Alam, Majid and Steinhoff, Martin},
title = {Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population},
journal = {Dermatologic Therapy},
year = {2022},
volume = {35},
number = {12},
doi = {10.1111/dth.15871}
}
EUVIMED